Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers

Singh, Neha, Krishnakumar, Subramanian, Kanwar, Rupinder K., Cheung, Chun Hei and Kanwar, Jagat R. 2014, Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers, Drug discovery today, vol. 20, no. 5, pp. 578-587, doi: 10.1016/j.drudis.2014.11.013.

Attached Files
Name Description MIMEType Size Downloads

Title Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers
Author(s) Singh, Neha
Krishnakumar, Subramanian
Kanwar, Rupinder K.
Cheung, Chun Hei
Kanwar, Jagat R.ORCID iD for Kanwar, Jagat R. orcid.org/0000-0003-3728-9568
Journal name Drug discovery today
Volume number 20
Issue number 5
Start page 578
End page 587
Total pages 10
Publisher Elsevier
Place of publication London, Eng.
Publication date 2014-11-26
ISSN 1878-5832
1359-6446
Summary Drug resistance is frequently found in cancer patients who have prolonged chemotherapeutic treatments. Overcoming this phenomenon to make therapy available to these patients is one of the most important features in developing effective cancer therapeutic strategies. Identification of drug resistance causative molecules is one of the most focused areas of cancer research today. Many molecules have been identified in conferring cancer cells the property of drug resistance, and various small molecule inhibitors have been developed to target these molecules to restore the sensitivity of different traditional chemotherapeutic agents, which are frequently found to exhibit reduced potency during prolonged treatment, in cancer patients. Survivin, a member of the inhibitor of apoptosis proteins (IAP) family, has been identified as one of the most crucial biomarkers in the recognition of drug resistance. Survivin is overexpressed in tumor cells, helping in its proliferation and survival, and its overexpression is positively correlated with poor prognosis for cancer patients. Targeted therapeutic measures to inhibit survivin in cancers, particularly drug-resistant tumors, are the recent focus of research for cancer treatment.
Language eng
DOI 10.1016/j.drudis.2014.11.013
Field of Research 111299 Oncology and Carcinogenesis not elsewhere classified
111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
1115 Pharmacology and Pharmaceutical Sciences
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©Elsevier
Persistent URL http://hdl.handle.net/10536/DRO/DU:30070210

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 41 times in TR Web of Science
Scopus Citation Count Cited 41 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 179 Abstract Views, 3 File Downloads  -  Detailed Statistics
Created: Wed, 04 Mar 2015, 09:24:59 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.